253 related articles for article (PubMed ID: 33189417)
1. The role of multiparametric magnetic resonance imaging in the selection and follow-up of patients undergoing active surveillance for prostate cancer. An European Section of Uro-Technology (ESUT) review.
Gómez Rivas J; Carrion DM; Chandrasekar T; Álvarez-Maestro M; Enikeev D; Martínez-Piñeiro L; Barret E
Actas Urol Esp (Engl Ed); 2021 Apr; 45(3):188-197. PubMed ID: 33189417
[TBL] [Abstract][Full Text] [Related]
2. Latest Evidence on the Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Insignificant Prostate Cancer: A Systematic Review.
Cantiello F; Manno S; Russo GI; Cimino S; Privitera S; Morgia G; Cicione A; Damiano R
Anticancer Agents Med Chem; 2018; 18(7):925-930. PubMed ID: 29303080
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Serial Multiparametric Magnetic Resonance Imaging and Subsequent Biopsy in Men with Low-risk Prostate Cancer Managed with Active Surveillance.
Hsiang W; Ghabili K; Syed JS; Holder J; Nguyen KA; Suarez-Sarmiento A; Huber S; Leapman MS; Sprenkle PC
Eur Urol Focus; 2021 Jan; 7(1):47-54. PubMed ID: 31147263
[TBL] [Abstract][Full Text] [Related]
4. Prostate Indeterminate Lesions on Magnetic Resonance Imaging-Biopsy Versus Surveillance: A Literature Review.
Gómez Rivas J; Giganti F; Álvarez-Maestro M; Freire MJ; Kasivisvanathan V; Martinez-Piñeiro L; Emberton M
Eur Urol Focus; 2019 Sep; 5(5):799-806. PubMed ID: 29525382
[TBL] [Abstract][Full Text] [Related]
5. Multiparametric magnetic resonance imaging facilitates reclassification during active surveillance for prostate cancer.
Fujihara A; Iwata T; Shakir A; Tafuri A; Cacciamani GE; Gill K; Ashrafi A; Ukimura O; Desai M; Duddalwar V; Stern MS; Aron M; Palmer SL; Gill IS; Abreu AL
BJU Int; 2021 Jun; 127(6):712-721. PubMed ID: 33043575
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer.
Chu CE; Lonergan PE; Washington SL; Cowan JE; Shinohara K; Westphalen AC; Carroll PR; Cooperberg MR
Eur Urol; 2020 Oct; 78(4):515-517. PubMed ID: 32631744
[TBL] [Abstract][Full Text] [Related]
7. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF
Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies: Time to Improve Radiologists' Training Program?
Luzzago S; Petralia G; Musi G; Catellani M; Alessi S; Di Trapani E; Mistretta FA; Serino A; Conti A; Pricolo P; Nazzani S; Mirone V; Matei DV; Montanari E; de Cobelli O
Clin Genitourin Cancer; 2019 Apr; 17(2):88-96. PubMed ID: 30527286
[TBL] [Abstract][Full Text] [Related]
9. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
Moldovan PC; Van den Broeck T; Sylvester R; Marconi L; Bellmunt J; van den Bergh RCN; Bolla M; Briers E; Cumberbatch MG; Fossati N; Gross T; Henry AM; Joniau S; van der Kwast TH; Matveev VB; van der Poel HG; De Santis M; Schoots IG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TB; Rouvière O
Eur Urol; 2017 Aug; 72(2):250-266. PubMed ID: 28336078
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance.
Macleod LC; Yabes JG; Fam MM; Bandari J; Yu M; Maganty A; Furlan A; Filson CP; Davies BJ; Jacobs BL
Eur Urol Focus; 2020 Mar; 6(2):242-248. PubMed ID: 31031042
[TBL] [Abstract][Full Text] [Related]
11. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
12. Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance.
Mamawala MK; Meyer AR; Landis PK; Macura KJ; Epstein JI; Partin AW; Carter BH; Gorin MA
BJU Int; 2020 Jun; 125(6):861-866. PubMed ID: 32039537
[TBL] [Abstract][Full Text] [Related]
13. Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis.
Cantiello F; Russo GI; Kaufmann S; Cacciamani G; Crocerossa F; Ferro M; De Cobelli O; Artibani W; Cimino S; Morgia G; Damiano R; Nikolaou K; Kröger N; Stenzl A; Bedke J; Kruck S
Prostate Cancer Prostatic Dis; 2019 May; 22(2):206-220. PubMed ID: 30487646
[TBL] [Abstract][Full Text] [Related]
14. Update and optimization of active surveillance in prostate cancer in 2021.
Rubio-Briones J; Pastor Navarro B; Esteban Escaño LM; Borque Fernando A
Actas Urol Esp (Engl Ed); 2021; 45(1):1-7. PubMed ID: 33070989
[TBL] [Abstract][Full Text] [Related]
15. The role of MRI in active surveillance for men with localized prostate cancer.
Recabal P; Ehdaie B
Curr Opin Urol; 2015 Nov; 25(6):504-9. PubMed ID: 26372037
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance imaging in prostate cancer detection and management: a systematic review.
Monni F; Fontanella P; Grasso A; Wiklund P; Ou YC; Randazzo M; Rocco B; Montanari E; Bianchi G
Minerva Urol Nefrol; 2017 Dec; 69(6):567-578. PubMed ID: 28488844
[TBL] [Abstract][Full Text] [Related]
17. Increasing Utilization of Multiparametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance.
Fam MM; Yabes JG; Macleod LC; Bandari J; Turner RM; Lopa SH; Furlan A; Filson CP; Davies BJ; Jacobs BL
Urology; 2019 Aug; 130():99-105. PubMed ID: 30940480
[TBL] [Abstract][Full Text] [Related]
18. Questions and answers on prostate multiparameter magnetic resonance imaging: Everything a urologist should know.
Catalá V; Salas D; Esquena S; Mateu S; Algaba F; Palou J; de la Torre P
Actas Urol Esp; 2016; 40(6):339-52. PubMed ID: 26920095
[TBL] [Abstract][Full Text] [Related]
19. Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer.
Parry MA; Srivastava S; Ali A; Cannistraci A; Antonello J; Barros-Silva JD; Ubertini V; Ramani V; Lau M; Shanks J; Nonaka D; Oliveira P; Hambrock T; Leong HS; Dhomen N; Miller C; Brady G; Dive C; Clarke NW; Marais R; Baena E
Eur Urol Oncol; 2019 Feb; 2(1):1-11. PubMed ID: 30929837
[TBL] [Abstract][Full Text] [Related]
20. Role of multiparametric prostate MRI in the management of prostate cancer.
O'Connor LP; Lebastchi AH; Horuz R; Rastinehad AR; Siddiqui MM; Grummet J; Kastner C; Ahmed HU; Pinto PA; Turkbey B
World J Urol; 2021 Mar; 39(3):651-659. PubMed ID: 32583039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
